Department of Pediatric Oncology and Hematology, Erasmus MC-Sophia Children's Hospital, Dr Molewaterplein 60, Rotterdam, The Netherlands.
Hematol Oncol Clin North Am. 2010 Feb;24(1):1-18. doi: 10.1016/j.hoc.2009.11.014.
Acute lymphoblastic leukemia (ALL), the most common type of cancer in children, is a heterogeneous disease in which many genetic lesions result in the development of multiple biologic subtypes. Today, with intensive multiagent chemotherapy, most children who have ALL are cured. The many national or institutional ALL therapy protocols in use tend to stratify patients in a multitude of different ways to tailor treatment to the rate of relapse. This article discusses the factors used in risk stratification and the treatment of pediatric ALL.
急性淋巴细胞白血病（ALL）是儿童中最常见的癌症类型，是一种异质性疾病，其中许多遗传病变导致多种生物学亚型的发展。如今，通过强化多药化疗，大多数患有 ALL 的儿童都可以被治愈。目前使用的许多国家或机构的 ALL 治疗方案倾向于通过多种不同方式对患者进行分层，以使治疗适应复发率。本文讨论了风险分层和儿童 ALL 治疗中使用的因素。
